The Goldman Sachs Group Forecasts Strong Price Appreciation for Denali Therapeutics (NASDAQ:DNLI) Stock

Denali Therapeutics (NASDAQ:DNLI) had its target price increased by stock analysts at The Goldman Sachs Group from $35.00 to $40.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. The Goldman Sachs Group’s price objective points to a potential upside of 94.51% from the company’s current price.

Other equities analysts also recently issued reports about the company. Wolfe Research started coverage on Denali Therapeutics in a research note on Monday, February 23rd. They issued a “peer perform” rating for the company. Robert W. Baird upped their target price on Denali Therapeutics from $29.00 to $32.00 and gave the company an “outperform” rating in a report on Thursday. Jefferies Financial Group restated a “buy” rating and issued a $40.00 price target on shares of Denali Therapeutics in a research report on Monday, March 2nd. Morgan Stanley reiterated an “overweight” rating and issued a $40.00 price objective on shares of Denali Therapeutics in a research report on Thursday, January 8th. Finally, UBS Group started coverage on shares of Denali Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Denali Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $34.64.

Denali Therapeutics Price Performance

Shares of NASDAQ DNLI traded down $1.91 during midday trading on Thursday, hitting $20.57. The company had a trading volume of 1,122,378 shares, compared to its average volume of 1,733,625. The firm has a market capitalization of $3.26 billion, a price-to-earnings ratio of -6.95 and a beta of 1.02. Denali Therapeutics has a twelve month low of $10.57 and a twelve month high of $23.77. The business has a 50-day simple moving average of $20.41 and a two-hundred day simple moving average of $17.80. The company has a quick ratio of 9.16, a current ratio of 9.16 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.02. During the same quarter last year, the business earned ($0.67) EPS. Equities research analysts anticipate that Denali Therapeutics will post -2.71 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Alexander O. Schuth sold 17,218 shares of Denali Therapeutics stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $284,097.00. Following the completion of the sale, the insider owned 282,828 shares in the company, valued at approximately $4,666,662. This trade represents a 5.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Ryan J. Watts sold 35,198 shares of the business’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $580,767.00. Following the completion of the transaction, the chief executive officer directly owned 296,833 shares of the company’s stock, valued at $4,897,744.50. The trade was a 10.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 12.50% of the company’s stock.

Institutional Investors Weigh In On Denali Therapeutics

Several hedge funds have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Denali Therapeutics by 4.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,507 shares of the company’s stock valued at $1,210,000 after buying an additional 3,432 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Denali Therapeutics by 58.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company’s stock worth $22,732,000 after acquiring an additional 614,555 shares during the period. Empowered Funds LLC grew its stake in Denali Therapeutics by 11.0% in the 1st quarter. Empowered Funds LLC now owns 20,639 shares of the company’s stock worth $281,000 after acquiring an additional 2,052 shares during the period. Woodline Partners LP raised its holdings in Denali Therapeutics by 13.5% in the 1st quarter. Woodline Partners LP now owns 113,517 shares of the company’s stock valued at $1,543,000 after acquiring an additional 13,517 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in shares of Denali Therapeutics by 120.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 8,236 shares of the company’s stock worth $115,000 after purchasing an additional 4,494 shares during the period. 92.92% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics News Roundup

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: FDA grants accelerated approval to AVLAYAH, the first brain‑penetrant enzyme replacement therapy for Hunter syndrome — validates Denali’s TransportVehicle™ platform, creates a near‑term commercial product, and comes with a Rare Pediatric Disease Priority Review Voucher that can be monetized or used for future filings. GlobeNewswire: FDA approval press release
• Positive Sentiment: Multiple analyst price‑target raises and bullish ratings today (BTIG to $38 buy, HC Wainwright to $42 buy, Robert W. Baird to $32 outperform) — these raise consensus upside and can attract institutional buying. Benzinga: analyst coverage roundup
• Positive Sentiment: Denali is hosting a conference call/webcast to discuss FDA approval and launch plans — investors will be watching commercialization timelines, pricing, supply and patient‑support programs for early revenue signals. Seeking Alpha: approval and launch transcript
• Neutral Sentiment: Regulatory designation context — approval was granted on a biomarker (CSF heparan sulfate) as a surrogate endpoint under accelerated approval; this speeds commercialization but leaves confirmatory evidence required. GlobeNewswire: approval details
• Neutral Sentiment: Short‑interest reporting in public feeds appears inconsistent/erroneous (entries showing 0 shares / NaN); current short data is not meaningful for interpreting immediate pressure. (Multiple short‑interest entries)
• Negative Sentiment: Continued approval is contingent on confirmatory Phase 2/3 COMPASS results — failure or delay in that trial could materially hurt valuation and limit label permanence. GlobeNewswire: confirmatory trial notes
• Negative Sentiment: Safety and use limitations — infusion‑related reactions, anaphylaxis risk, reports of anemia and rare kidney issues, and the label’s restriction against combining with other ERTs may limit uptake and complicate reimbursement. GlobeNewswire: safety and limitations
• Negative Sentiment: Recent insider sales and reported institutional rebalancing (Quiver/Globe reporting) could add near‑term supply pressure on the stock as holders take profits after the run‑up. QuiverQuant: insider & institutional activity

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.